Premium
Identification of Perfusion Abnormalities Using FSO69, a Novel Contrast Agent, in Conscious Dogs
Author(s) -
MOBAREK SAMEH,
KATES MARC,
MEZA MARIO,
MORENO CARLOS,
REVALL SUSAN,
BARBEE WAYNE,
MURGO JOSEPH P.,
CHEIRIF JORGE
Publication year - 1997
Publication title -
echocardiography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 62
eISSN - 1540-8175
pISSN - 0742-2822
DOI - 10.1111/j.1540-8175.1997.tb00732.x
Subject(s) - perfusion , medicine , perfusion scanning , breathing , cardiology , nuclear medicine , anesthesia , radiology
Recent advances in the production of echocardiographic contrast agents has resulted in the ability to delineate areas of hypoperfusion after coronary occlusions and stenoses following their intravenous injection. Most of these studies though have been done in open chest animals. This study was done to determine if we could assess myocardial perfusion following the intravenous administration of FSO69, a suspension of perfluoropropane filled albumin microspheres (3.6 μm average microbubble size, concentration 8 × 10 8 ), in spontaneously breathing closed chest dogs. Twenty‐seven mongrel dogs were instrumented on day 1. The chest was then closed and the dogs were restudied 3–7 days later, while spontaneously breathing. Homogeneous perfusion was observed in most dogs by all three independent and blinded observers. Perfusion abnormalities were likewise identified in most instances by all blinded reviewers on interventions designed to decrease regional blood flow. A good correlation between perfusion defect size between investigators was observed. In summary, our data suggest that FSO69 can be used to assess regional myocardial perfusion in spontaneously breathing dogs. These results support its use in humans.